Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

The following is a summary of “Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease,” ...

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

There's new research linking senolytics to helping slow down Alzheimer's progression. Here's how and what experts have to say ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in people with early Alzheimer's disease.

According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...